Thiazolidinyl- and perhydrothiazinylphosphamidesters: Toxicity and preliminary antitumour evaluation

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 11-12, 1997, Pages 623-631

  Voelcker, G ^a   Bielicki, L ^a   Hohorst, H J ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antitumour activity; Thiazolidines and perhydrothiazines of aldophosphamide; Toxicity

Indexed keywords

ALDOPHOSPHAMIDE PERHYDROTHIAZINE; ALDOPHOSPHAMIDE THIAZOLIDINE; CYCLOPHOSPHAMIDE; OXAZAPHOSPHORINE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHORAMIDE MUSTARD; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOSTASIS; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG SYNTHESIS; LD 50; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; INJECTIONS, INTRAPERITONEAL; LEUKEMIA P388; MALE; MAST-CELL SARCOMA; MICE; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; PROTEIN BINDING; THIAZINES; THIAZOLES; THIAZOLIDINES; TISSUE DISTRIBUTION;

EID: 0031456462     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050116     Document Type: Article

References (33)

1. Bielicki L, Voelcker G, Hohorst HJ (1983) Enzymatic toxicogenation of "activated" cyclophosphamide by 3′-5′exonucleases. J Cancer Res Clin Oncol 105:27-29
2. Bielicki L, Voelcker G, Hohorst HJ (1984) Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3′-5′ exonuclease. J Cancer Res Clin Oncol 107:195-198
3. Brock N (1976) Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC 26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds. Cancer Treat Rep 60:301-308
4. Brock N, Hohorst HJ (1963) Über die Aktivierung von Cyclophosphamid in vivo und in vitro. Arzneimibtelforschung 13:1021-1031
5. Brock N, Hohorst HJ (1977) The problem of specificity and selectivity of alkylating cytostatics: studies on N-2-chloroethylamido-oxazaphosphorines. Z Krebsforsch Klin Onkol 88:185-215
6. Connors TA, Grover PL, Mc Loughlin AM (1970) Microsomal activation of cyclophosphamide in vivo. Biochem Pharmacol 19:1533-1535
7. Connors TA, Foster AB, Gilsenan AM, Jarman M, Tisdale MJ (1972) Observations on the metabolism of cyclophosphamide. Biochem Pharmacol 21:1373-1376
8. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1974) Some studies of the active intermediate formed in the microsomal metabolism of cyclophosphamide and ifosphamide. Biochem Pharmacol 23:115-129
9. Dausmann D (1988) Synthese von N,N-Bis-(2-chlorethyl-)-Phosphorsäureamid-Derivaten als Substrat für 3′-5′Exonukleasen und Untersuchungen zur Umsetzung von "aktiviertem cyclophosphamid" mit 1,2- und 1,3 Dinukleophilen. Inaugural Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften, Fachbereich Biochemie, Pharmazie und Lebensmittelchemie der Johann Wolfgang Goethe-Universität Frankfurt /M
10. Draeger U, Peter G, Hohorst HJ (1976) Deactivation of cyclophosphamide (NSC 26271) metabolites by sulfhydryl compounds. Cancer Treat Rep 60:423-427
11. Friedman OM, Boger E (1961) Colorimetric estimation of nitrogen mustards in aqueous media. Anal Chem 33:906-910
12. Grasetti DR, Murray TF Jr (1967) Determination of sulfhydryl groups with 2,2 and 4,4dithiodipyridine. Arch Biochem Biophys 119:41-49
13. Haeglsperger R (1980) Pharmakokinetische Untersuchungen über den Cyclophosphamidstoffwechsel bei der Maus. Inaugural Dissertation, Fachbereich Humanmedizin, Frankfurt/M
14. Hohorst HJ, Ziemann A, Brock N (1971) 4-Ketocyclophosphamide a metabolite of cyclophosphamide. Formation, chemical and biological properties. Arzneimibtelforschung 21:1254-1257
15. Hohorst HJ, Draeger U, Peter G, Voelcker G (1976) The problem of oncostatic specificity of cyclophosphamide (NSC-2627 1): studies on reactions that control the alkylating and cytotoxic activity. Cancer Treat Rep 60:309-315
16. Hohorst HJ, Bielicki L, Voelcker G (1986) The enzymatic basis of cyclophosphamide specificity. Adv Enzyme Regul 25:99-122
17. Hohorst HJ, Bielicki L, Müller K, Voelcker G (1988) Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide-esters, J Cancer Res Clin Oncol 114:309-311
18. Hübscher U, Thömmes P (1992) DNA polymerase ε: in search of a function. Trends Biochem Sci 17:55-58
19. Jungkamp W (1990) Aktive Anreicherung von Aldophosphamidthiazolidin-4-carbonsäure in tierischen Zellen - Untersuchungen an Ehrlich-Ascites-Tumorzellen. Inaugural Dissertation zur Erlangung des Doktorgrades der Zahnmedizin des Fachbereichs Humanmedizin der Johann Wolfgang Goethe-Universität Frankfurt/M
20. Kromphardt H (1963) Die Aufnahme von Taurin in Ehrlich Ascites Tumorzellen. Biochem Z 339:233-254
21. Lehman IR, Richardson CC (1964) The deoxyribonuclease of Escherichia coli. IV. An exonuclease activity present in purified preparations of deoxyribonucleic acid polymerase. J Biol Chem 239:233-241
22. Peter G, Hohorst HJ (1979) Synthesis and preliminary anti-tumor evaluation of 4(SR)-sulfido-cyclophosphamide. Cancer Chemother Pharmacol 3:181-188
23. Peter G, Wagner T, Hohorst HJ (1976) Studies on 4-hydroperoxy-cyclophosphamide (NSC 181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC 26271) derivatives. Cancer Treat Rep 60:429-435
24. Sladek NE (1972) Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Cancer Res 32:535-542
25. Sladek NE (1973a) Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide. Cancer Res 33:651-658
26. Sladek NE (1973b) Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res 33:1150-1159
27. Voelcker G, Wagner T, Hohorst HJ (1976) Identification and pharmacokinetics of cyclophosphamide (NSC 26271) metabolites in vivo. Cancer Treat Reps, 60:415-422
28. Voelcker G, Giera HP, Jäger L, Hohorst HJ (1977) Bindung von Cyclophosphamid und Cyclophosphamid Metaboliten an Serum Albumin Z Krebsforsch 91:127-142
29. Voelcker G, Fortmeyer HP (1979) Die intravenöse Injektion über den retrobulbären Plexus bei der Maus. Z Versuchtierkd 21:177-181
30. Voelcker G, Haeglsperger R, Hohorst HJ (1979) Fluorometrische Bestimmung von "aktiviertem" Cyclophosphamid und Ifosfamid im Blut. J Cancer Res Clin Oncol 93:233-240
31. Voelcker G, Bielicki L, Hohorst HJ (1981) Evidence for enzymatic toxification of "activated" cyclophosphamide (4-hydroxycyclophosphamide) J Cancer Res Clin Oncol 99A:58-59
32. Voelcker G, Haeglsperger R (1982) Die Pharmakokinetik von Cyclophosphamid und Cyclophosphamid. Metaboliten bei der Mans and ihr Einfluß auf die therapeutische Wirkung von "aktiviertem" Cyclophosphamid (4. Hydroxyclyclophosphamid) Arzneim Forsch Drug Res. 32(I) 6:639-647
33. Wagner T, Heydrich D, Voelcker G, Hohorst HJ (1980) Butspiegel und Urin-Ausscheidung von aktiviertem Cyclophosphamid und seinen Deaktivierungsprodukten beim Menschen. J Cancer Res Clin Oncol 96:79-92